Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
TB-500 vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
TB-500 is distinguished by a seven-amino-acid N-acetylated fragment of thymosin beta-4. No human exposure, PK/PD, safety, or efficacy study was located; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
TB-500 is distinguished in the current record by a seven-amino-acid N-acetylated fragment of thymosin beta-4. No human exposure, PK/PD, safety, or efficacy study was located. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
TB-500: No direct human evidence. Liraglutide: Mature human evidence.
Regulatory historyLiraglutide
TB-500: Not approved; PCAC recommended 503A inclusion. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
TB-500
- Wound healing — proposed, not demonstrated in humans
- In-vitro metabolism and fibroblast migration
- Animal pharmacokinetics and anti-doping detection
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
TB-500PCAC yes; FDA pending
Not FDA approved. PCAC voted 8–6 with one abstention on July 23, 2026 to recommend 503A-list inclusion; the recommendation is nonbinding and final FDA action was not located by July 25.
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
Evidence depthEvidence, not a winner
TB-500Preclinical only
Analytical identity studies, equine and rat metabolism research, and an in-vitro fibroblast assay. No direct human evidence.
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
Weight outcomesEvidence, not a winner
TB-500No human evidence
No controlled human weight or body-composition study was located.
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
Type 2 diabetesEvidence, not a winner
TB-500No human evidence
No controlled human diabetes study was located.
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
Obstructive sleep apnoeaEvidence, not a winner
TB-500No human evidence
No controlled human obstructive-sleep-apnoea study was located.
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
Cardiovascular outcomesEvidence, not a winner
TB-500No human evidence
No human cardiovascular study was located. Cardiac research involving full-length thymosin beta-4 cannot be assigned to TB-500.
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
Administration and handlingEvidence, not a winner
TB-500Nomination, not guidance
A withdrawn compounding nomination described subcutaneous and intramuscular injection, but FDA found no human study of either route and no approved dosing or reconstitution procedure.
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether TB-500 has any clinically meaningful human effect, its human safety, and whether a labeled material is actually the stated free base or acetate.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
TB-500
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.